SCHEMBL870174

SCHEMBL870174

COC(=O)c1ccc(C=O)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.47
PIM1 P11309 1/20 0.47
PIM3 Q86V86 1/20 0.47
NR4A2 P43354 5/20 0.46
CREBBP Q92793 1/20 0.46
LMNA P02545 3/20 0.46
TSHR P16473 1/20 0.46
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 5/20 0.44
CFTR P13569 1/20 0.44
HSD17B10 Q99714 1/20 0.44
POLB P06746 2/20 0.43
ATM Q13315 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
RAB9A P51151 1/20 0.42
MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3897604 0.90 PIM1 (0.53) BRD4PIM1PIM3NR4A2CREBBP
SCHEMBL70381 0.85 BRD4 (0.59) BRD4NR4A2CREBBPLMNATSHR
SCHEMBL29434198 0.85 BRD4 (0.59) BRD4NR4A2CREBBPLMNATSHR
SCHEMBL30717654 0.85 BRD4 (0.46) BRD4NR4A2CREBBPLMNATSHR
SCHEMBL883625 0.85 BRD4 (0.46) BRD4NR4A2CREBBPLMNATSHR
SCHEMBL1665898 0.82 ALDH1A1 (0.47) LMNAKDM4EALDH1A1HSD17B10POLB
SCHEMBL1036677 0.82 HPGD (0.46) BRD4NR4A2CREBBPLMNATSHR
SCHEMBL1036678 0.82 HPGD (0.46) BRD4NR4A2CREBBPLMNATSHR
SCHEMBL870987 0.81 CYP1A2 (0.49) BRD4NR4A2CREBBPLMNAKDM4E
SCHEMBL870986 0.81 CYP1A2 (0.49) BRD4NR4A2CREBBPLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119490406-A Preparation method of 4-formylnaphthalene-1-carboxylic acid methyl ester 长沙创新药物工业技术研究院有限公司 2025-02-21 CN claimed
CN-117886695-A Synthesis method of aforana key intermediate 4-formyl-1-methyl naphthoate 浙江工业大学 2024-04-16 CN claimed
CN-117776883-A Preparation method of aromatic ketone compound containing diaryl methane structure 湖南科技大学 2024-03-29 CN claimed
US-20260070879-A1 ISOXAZOLINE DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2026-03-12 US disclosed
US-12497370-B2 Isoxazoline derivatives ELANCO TIERGESUNDHEIT AG (CH) 2025-12-16 US disclosed
CN-120004816-A Isoxazoline derivatives 礼蓝动物保健有限公司 2025-05-16 CN disclosed
CN-115210221-B Isoxazoline derivatives as pesticides 礼蓝动物保健有限公司 2025-03-18 CN disclosed
CN-119490406-A Preparation method of 4-formylnaphthalene-1-carboxylic acid methyl ester 长沙创新药物工业技术研究院有限公司 2025-02-21 CN disclosed
CN-119490406-A Preparation method of 4-formylnaphthalene-1-carboxylic acid methyl ester 长沙创新药物工业技术研究院有限公司 2025-02-21 CN disclosed
CN-119490406-A Preparation method of 4-formylnaphthalene-1-carboxylic acid methyl ester 长沙创新药物工业技术研究院有限公司 2025-02-21 CN disclosed
CN-117886695-A Synthesis method of aforana key intermediate 4-formyl-1-methyl naphthoate 浙江工业大学 2024-04-16 CN disclosed
US-20040127574-A1 Aminoethanol derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-07-01 US disclosed
EP-1362846-A1 AMINOETHANOL DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-11-19 EP disclosed
US-6613942-B1 Nonpeptide; 4-hydroxy benzoic acid hydrazides NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-0994848-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-04-26 EP disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 WO disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 WO disclosed
US-4016195-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1977-04-05 US disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed
US-3957846-A OPTICAL BRIGHTENERS, LACQUERS, SYNTHETIC FIBERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127574-A1 Aminoethanol derivatives CETP, LCAT, MTTP BRD4 461/4885PIM1 3393/4885PIM3 3949/4885
US-12497370-B2 Isoxazoline derivatives CYP3A7, CYP4X1, CYP2A7 BRD4 1245/4885PIM1 3109/4885PIM3 3019/4885
US-20260070879-A1 ISOXAZOLINE DERIVATIVES CHRM1, CBR3, AFF1 BRD4 788/4885PIM1 3607/4885PIM3 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.